BioCentury | Jul 1, 2013
Finance

2Q Stock Wrap-Up: If it ain't broke

...D. Western Therapeutics Institute Inc. ; specialty pharma KV Pharmaceutical Co. ; neuro-inflammatory disorder company Pharmos Corp....
...NASDAQ:IRWD), Cambridge, Mass. KV Pharmaceutical Co. (OTCQB:KVPHQ), St. Louis, Mo. PeptiDream Inc. (Tokyo:4587), Tokyo, Japan Pharmos Corp....
BioCentury | Apr 15, 2013
Clinical News

Pharmos, Bausch & Lomb Pharmaceuticals Inc. regulatory update

...Lomb has rights to manufacture and market Lotemax in the U.S. and certain international markets. Pharmos Corp....
BioCentury | Apr 15, 2013
Company News

Pharmos management update

Pharmos Corp. (PARS), Alachua, Fla. Business: Ophthalmic Leaving: Alan Mark, acting CFO, to pursue other business opportunities WIR Staff Ophthalmic...
BioCentury | Dec 3, 2012
Clinical News

Levotofisopam S-tofisopam: Phase IIa data

...on day 7. Data were presented at the American College of Rheumatology meeting in Washington. Pharmos...
...it is actively seeking a partner for the product to continue clinical development in gout. Pharmos Corp....
BioCentury | Jul 30, 2012
Tools & Techniques

Network revival

...acetyltransferase; cyclin dependent kinase 2 (CDK2) and CDK5 . ETS2101 had previously been developed by Pharmos Corp....
...and Institutions Mentioned e-Therapeutics plc (LSE:ETX), Newcastle, U.K. Hebrew University of Jerusalem , Jerusalem, Israel Pharmos Corp....
BioCentury | Jan 16, 2012
Clinical News

Levotofisopam: Phase IIa started

...daily on days 1 and 7 and thrice-daily on days 2-6 in about 20 patients. Pharmos Corp....
BioCentury | Aug 4, 2011
Distillery Therapeutics

Indication: Neurology

...with vehicle. Next steps include studying the effects of CNR2 agonists in rats and primates. Pharmos Corp.'s...
BioCentury | Oct 26, 2009
Company News

Pharmos gastrointestinal news

...endpoint in a Phase IIb trial to treat irritable bowel syndrome (IBS). At June 30, Pharmos...
...million in cash and a six-month operating loss of $5.2 million (see BioCentury, Sept. 21). Pharmos Corp....
BioCentury | Sep 21, 2009
Clinical News

Dextofisopam: Phase IIb data

...month 1 vs. placebo. The 100 and 300 mg doses of dextofisopam missed the endpoints. Pharmos Corp....
BioCentury | Apr 13, 2009
Clinical News

Dextofisopam: Completed Phase IIb enrollment

...200 and 300 mg of dextofisopam given twice daily vs. placebo for 12 weeks. Additionally, Pharmos...
...trial and operations through 2009. The financing is expected to close this month. In March, Pharmos...
...was seeking to raise additional capital necessary to complete the trial (see BioCentury, March 9). Pharmos Corp....
Items per page:
1 - 10 of 201
BioCentury | Jul 1, 2013
Finance

2Q Stock Wrap-Up: If it ain't broke

...D. Western Therapeutics Institute Inc. ; specialty pharma KV Pharmaceutical Co. ; neuro-inflammatory disorder company Pharmos Corp....
...NASDAQ:IRWD), Cambridge, Mass. KV Pharmaceutical Co. (OTCQB:KVPHQ), St. Louis, Mo. PeptiDream Inc. (Tokyo:4587), Tokyo, Japan Pharmos Corp....
BioCentury | Apr 15, 2013
Clinical News

Pharmos, Bausch & Lomb Pharmaceuticals Inc. regulatory update

...Lomb has rights to manufacture and market Lotemax in the U.S. and certain international markets. Pharmos Corp....
BioCentury | Apr 15, 2013
Company News

Pharmos management update

Pharmos Corp. (PARS), Alachua, Fla. Business: Ophthalmic Leaving: Alan Mark, acting CFO, to pursue other business opportunities WIR Staff Ophthalmic...
BioCentury | Dec 3, 2012
Clinical News

Levotofisopam S-tofisopam: Phase IIa data

...on day 7. Data were presented at the American College of Rheumatology meeting in Washington. Pharmos...
...it is actively seeking a partner for the product to continue clinical development in gout. Pharmos Corp....
BioCentury | Jul 30, 2012
Tools & Techniques

Network revival

...acetyltransferase; cyclin dependent kinase 2 (CDK2) and CDK5 . ETS2101 had previously been developed by Pharmos Corp....
...and Institutions Mentioned e-Therapeutics plc (LSE:ETX), Newcastle, U.K. Hebrew University of Jerusalem , Jerusalem, Israel Pharmos Corp....
BioCentury | Jan 16, 2012
Clinical News

Levotofisopam: Phase IIa started

...daily on days 1 and 7 and thrice-daily on days 2-6 in about 20 patients. Pharmos Corp....
BioCentury | Aug 4, 2011
Distillery Therapeutics

Indication: Neurology

...with vehicle. Next steps include studying the effects of CNR2 agonists in rats and primates. Pharmos Corp.'s...
BioCentury | Oct 26, 2009
Company News

Pharmos gastrointestinal news

...endpoint in a Phase IIb trial to treat irritable bowel syndrome (IBS). At June 30, Pharmos...
...million in cash and a six-month operating loss of $5.2 million (see BioCentury, Sept. 21). Pharmos Corp....
BioCentury | Sep 21, 2009
Clinical News

Dextofisopam: Phase IIb data

...month 1 vs. placebo. The 100 and 300 mg doses of dextofisopam missed the endpoints. Pharmos Corp....
BioCentury | Apr 13, 2009
Clinical News

Dextofisopam: Completed Phase IIb enrollment

...200 and 300 mg of dextofisopam given twice daily vs. placebo for 12 weeks. Additionally, Pharmos...
...trial and operations through 2009. The financing is expected to close this month. In March, Pharmos...
...was seeking to raise additional capital necessary to complete the trial (see BioCentury, March 9). Pharmos Corp....
Items per page:
1 - 10 of 201